TABLE 2.
Groups and sensitization rate of mice in the present study.
| Groups | Mice | Score | Sensitization rate (%) | |||
|---|---|---|---|---|---|---|
| n | 0 | 1 | 2 | 3 | ||
| Blank control | 5 | 5 | 0 | 0 | 0 | 0.00 |
| Vehicle control | 5 | 5 | 0 | 0 | 0 | 0.00 |
| TCE treatment | 30 | 22 | 7 | 1 | 0 | 26.67 |
| TCEpos | 8 | 0 | 7 | 1 | 0 | — |
| TCEneg | 22 | 22 | 0 | 0 | 0 | — |
| sCD59-cys + TCE treatment | 26 | 19 | 5 | 2 | 0 | 26.92 |
| CD59 + TCEpos | 7 | 0 | 5 | 2 | 0 | — |
| CD59 + TCEneg | 19 | 19 | 0 | 0 | 0 | — |
| MCC950 + TCE treatment | 36 | 23 | 9 | 4 | 0 | 36.11 |
| MCC950 + TCEpos | 13 | 0 | 9 | 4 | 0 | — |
| MCC950 + TCEneg | 23 | 23 | 0 | 0 | 0 | — |
TCE, trichloroethylene; pos, positive; neg, negative; sCD59-cys, a specific inhibitor of C5b-9 assembly; MCC950, a specific antagonist of NLRP3.